Published Date : 2025-Mar-27
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Technology has revolutionized genetic engineering, enabling precise genome editing with vast applications in medicine, agriculture, and biotechnology. As of 2025, the CRISPR market is expected to grow exponentially, driven by increasing investments in gene therapy, agricultural biotechnology, and drug discovery.
The Market size was US$ 3.3 Billion in 2022. Covid-19's impacts have been unprecedented and staggering on a global scale, with the pandemic leading to positive demand shocks for the CRISPR technology market across all domains and regions.
The market is projected to reach US$ 25.8 Billion by 2033, growing at a CAGR of 24.5 % during the forecast period (2025-2033).
Overview: CRISPR Therapeutics is a biotechnology company specializing in CRISPR-Cas9 gene-editing technology to develop transformative therapies for serious diseases. The company is at the forefront of gene therapy, regenerative medicine, and oncology treatments, leveraging CRISPR-based solutions to address genetic disorders.
As one of the pioneers in CRISPR-based medicine, CRISPR Therapeutics is shaping the future of gene therapy, oncology, and regenerative medicine. With multiple therapies in clinical trials and a growing market presence, the company is expected to play a critical role in the $10B+ CRISPR market by 2025.
Overview Editas Medicine is a pioneering biotechnology company specializing in CRISPR-based gene-editing therapies. The company focuses on developing treatments for genetic diseases, inherited retinal disorders, and hematological conditions using both CRISPR-Cas9 and CRISPR-Cas12a technologies.
With breakthroughs in genetic medicine, strong clinical progress, and a focus on precision gene editing, Editas Medicine is shaping the future of CRISPR-based therapies.
Overview: Intellia Therapeutics is a leading biotechnology company specializing in in vivo and ex vivo CRISPR-based gene-editing therapies. It focuses on developing one-time treatments for genetic diseases, leveraging CRISPR-Cas9 technology to edit disease-causing genes inside the human body.
With cutting-edge gene-editing technologies, strong clinical progress, and a focus on in vivo CRISPR therapies, Intellia is poised to revolutionize medicine in the coming years.
Overview: Beam Therapeutics is a biotechnology leader specializing in precision gene editing using base editing—a next-generation CRISPR technology that makes precise single-letter (nucleotide) changes in the DNA without causing double-strand breaks. The company focuses on developing one-time, curative treatments for genetic diseases.
With cutting-edge base editing technology, a robust pipeline, and strong clinical momentum, Beam Therapeutics is set to transform the future of genetic medicine.
Overview: Caribou Biosciences is a biotechnology company specializing in CRISPR genome editing with a primary focus on developing next-generation cell therapies for cancer. Caribou’s proprietary chRDNA (CRISPR hybrid RNA-DNA) technology offers improved precision and efficiency in genetic modifications compared to traditional CRISPR-Cas9 systems.
With its cutting-edge CRISPR technology, promising cell therapy pipeline, and strong clinical momentum, Caribou Biosciences is shaping the future of cancer treatment.
Overview: Synthego is a leading biotechnology company specializing in AI-powered genome engineering, providing high-quality CRISPR gene-editing tools, synthetic guide RNAs, and automation solutions. The company aims to democratize CRISPR research by making gene editing more accessible, scalable, and efficient for scientists worldwide.
With cutting-edge AI-driven tools, automated genome engineering, and strong collaborations, Synthego is transforming CRISPR research and therapeutics.
Overview: Mammoth Biosciences is a biotechnology company pioneering the use of CRISPR-based diagnostics and therapeutics. The company specializes in developing next-generation CRISPR systems, including Cas12, Cas13, and Cas14, to create ultrasensitive molecular detection tools and novel gene-editing therapies.
Mammoth is co-founded by Jennifer Doudna, a Nobel Prize winner and one of the inventors of CRISPR. The company is at the forefront of expanding CRISPR beyond gene editing, particularly in disease diagnostics and in vivo gene therapies.
With groundbreaking CRISPR-based diagnostics and gene-editing therapeutics, Mammoth Biosciences is expanding the frontiers of CRISPR technology beyond traditional applications.
Overview: ERS Genomics is a biotechnology licensing company that provides access to foundational CRISPR-Cas9 intellectual property (IP) for commercial and research applications. Founded by Emmanuelle Charpentier, one of the co-discoverers of CRISPR-Cas9 and a 2020 Nobel Laureate, ERS Genomics enables companies across various industries to leverage CRISPR technology legally and efficiently.
Unlike other CRISPR companies focused on developing therapeutics or diagnostics, ERS Genomics primarily offers licensing rights to non-exclusive CRISPR-Cas9 patents, ensuring that biotech firms, pharmaceutical companies, and research institutions can use the technology without legal barriers.
ERS Genomics plays a crucial role in making CRISPR-Cas9 accessible to the biotech industry, allowing companies worldwide to develop new gene-editing applications without legal restrictions.
Overview: Cellectis is a clinical-stage biopharmaceutical company specializing in gene-edited allogeneic (off-the-shelf) CAR-T cell therapies for cancer treatment. Unlike many CRISPR-focused companies, Cellectis primarily utilizes TALEN (Transcription Activator-Like Effector Nucleases) alongside CRISPR to develop next-generation immunotherapies and gene-editing solutions.
By engineering allogeneic (donor-derived) T-cells, Cellectis aims to revolutionize cancer treatment by making CAR-T therapy more accessible, cost-effective, and scalable compared to traditional autologous (patient-derived) approaches.
Headquarters: Shiga, Japan
Founded: 2002
Employees: Approx. 1,000 (2024)
Revenue (2024): Approx. $500 million
Regional Presence: Asia-Pacific leader, expanding collaborations in the US and Europe
Overview: Takara Bio is a biotechnology company specializing in genome editing, gene therapy, and life sciences research. The company is a global leader in CRISPR-Cas9 and TALEN gene-editing technologies, stem cell research, and next-generation sequencing (NGS) solutions. Takara Bio serves a broad range of industries, including biopharmaceuticals, regenerative medicine, and molecular diagnostics.
As part of the Takara Holdings Group, Takara Bio has been at the forefront of biotechnology innovation since its inception, continuously expanding its global presence in the genomics and gene therapy sectors.
Takara Bio continues to bridge the gap between gene editing and clinical applications, driving global innovation in CRISPR-based therapies and diagnostics.
According to this market tendency, the biomedical sector is anticipated to have a significant impact on the market for CRISPR technology in the near future. The term "biomedical" describes the application of biological and physiological concepts to clinical medicine, which includes the identification, management, and avoidance of illnesses and conditions.
The biomedical industry's use of CRISPR technology has demonstrated great promise for the creation of innovative therapies and treatments for a variety of illnesses and disorders. In order to cure genetic disorders, faulty genes can be fixed or replaced with healthy ones using CRISPR technology. By focusing on particular genes linked to a person's illness, CRISPR can also be used to create personalized medicine, leading to more precise and effective treatments.
Furthermore, the biomedical industry has a large market size and is constantly growing due to the increasing prevalence of chronic diseases and the aging population worldwide. As a result, the demand for effective and personalized treatments is increasing, which is expected to drive the growth of the CRISPR technology market.
The global CRISPR technology market is projected to surpass $10 billion by 2025, with key regional contributions:
CRISPR technology continues to shape the future of medicine, agriculture, and synthetic biology. The market is dominated by North American companies, with strong European and Asian players expanding their influence. As gene editing gains regulatory approvals, these companies will lead the transformation of healthcare and biotechnology in the years to come.
Would you like me to add more details on specific companies or market trends? Let me know! CLICK HERE
Intellectual Market Insights Research is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including, Semiconductor, aerospace, Automation, Agriculture, Food & Beverages, Automotive, Chemicals and Materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports.
